MedPath

High versus Low volume plasma exchange in liver failure

Not Applicable
Conditions
Health Condition 1: K729- Hepatic failure, unspecified
Registration Number
CTRI/2019/06/019660
Lead Sponsor
Post Graduate Institute of Medical Education and Research Chandigarh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. First episode of de-compensation with AARC-ACLF (APASL (Asian Pacific Association for the Study of the Liver) ACLF (Acute on Chronic Liver Failure) Research Consortium (AARC) grade I or II (AARC score <10)

2.No evidence of active infection

3.Willing to give informed consent for the procedure

Exclusion Criteria

1.Pregnancy

2.Co-existing HCC or extra-hepatic malignancy

3.Microbiological or radiological evidence of active infection

4.Active hemorrhage

5.Multi-organ failure(>= 3 organ failures)

6.APASL-AARC score >10

7.Known allergy to Plasma, Protamine or Heparin.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy (in term of change of clinical grade of severity) and tolerability (in terms of adverse events related to procedure) of standard (one) volume plasma exchange Vs high volume plasma exchange in acute on chronic liver failure patientsTimepoint: Day 0, Day 4, day 30 and day 90
Secondary Outcome Measures
NameTimeMethod
To estimate the effect of different volume exchange procedure on biochemical parameters and Cytokine levels (IL6 IL10 and TNFα) <br/ ><br>To compare the effect of different volume exchange procedures on 30 & 90 day mortality. <br/ ><br>Timepoint: Day 0 to day 4 for biochemical and laboratory parameters and day 30 and day 90 for mortality
© Copyright 2025. All Rights Reserved by MedPath